title: [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
abstract: OBJECTIVE
  Heparin-induced thrombocytopenia is a relatively common and potentially serious adverse complication of heparin treatment. After heparin withdrawal initiation of an alternative anticoagulant is often indicated. Org 10172 or Orgaran is a mixture of several non-heparin low molecular weight glycosaminoglycans with proven antithrombotic efficacy. Unlike low molecular weight heparins, Org 10172 has a low cross reaction rate (about 10%) with the heparin-dependent antibody.
  
  
  METHODS
  We present nine patients with heparin induced thrombocytopenia. Org 10172 was prescribed to treat or to prevent a thromboembolic event.
  
  
  RESULTS
  Seven patients required further parenteral anticoagulant at diagnosis of heparin-induced thrombocytopenia. Org 10172 was given at prophylactic doses for three patients with a high thrombosis risk and at therapeutic doses for four patients who presented either a venous or an arterial thrombosis related to thrombocytopenia. Two patients presented heparin-induced thrombocytopenia four to six years earlier and needed a parenteral anticoagulation treatment in a post-operative period.
  
  
  CONCLUSIONS
  For the nine patients, Org 10172 was a safe and effective antithrombotic treatment. However, strict monotoring of the platelet count is absolutely mandatory during Org 10172 therapy.
authors.affiliation: Département d'Hématologie, Hôpital Nord, CHRU de Saint-Etienne.
authors.forename: B
authors.initials: B
authors.lastname: Tardy-Poncet
authors.forename: J
authors.initials: J
authors.lastname: Reynaud
authors.forename: B
authors.initials: B
authors.lastname: Tardy
authors.forename: P
authors.initials: P
authors.lastname: Mahul
authors.forename: P
authors.initials: P
authors.lastname: Mismetti
authors.forename: A M
authors.initials: AM
authors.lastname: Beraud
authors.forename: M A
authors.initials: MA
authors.lastname: Rebaud
authors.forename: M
authors.initials: M
authors.lastname: Bayon
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid
vernacular_title: Thrombopénie induite par l'héparine: traitement par l'ORG 10172. Tolérance et efficacité.